Outcome of pediatric patients with severe aplastic anemia
Keywords:
-Abstract
-
Downloads
Download data is not yet available.
References
1. Gluckman E, Devergie A, Poros A, et al. Results of immunogsuppression in 170 cases of severe aplastic anaemia. Report of the European Group of Bone Marrow Transplant (EGBMT). Br
J Haematol 1982;51:541-50.
2. Kwon JH, Kim I, Lee YG, et al. Clinical course of non-severe aplastic anemia in adults. Int J Hematol. 2010; 91:770-5.
3. Peinemann F, Grouven U, Kröger N, Bartel C, Pittler MH, Lange S. First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. PLoS One 2011 25; 6:e18572.
4. Marsh JC. Management of acquired aplastic anemia. Blood Rev. 2005 May; 19:143-51.
5. Kojima S. Treatment of acquired aplastic anemia in children. Hematology. 2012;17(Suppl 1):S11-4.
6. Bacigalupo A. How I treat acquired aplastic anemia. Blood 2017;129:1428-36.
7. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants
for young patients with severe acquired aplastic anemia. Blood 2007 15;110:1397-400.
8. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430-8.
9. Narita A, Zhu X, Muramatsu H, et al. Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia. Br J Haematol 2019;187:227-37.
10. Pongtanakul B, Das PK, Charpentier K, Dror, Y. Outcome of children with aplastic anemia treated with immunosuppressive
therapy. Pediatr Blood cancer 2008;50:52-7
11. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N
Engl J Med 2017;376:1540-50
12. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl
J Med. 2012;367:11-9.
13. Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol 2019;6:e562-e572.
J Haematol 1982;51:541-50.
2. Kwon JH, Kim I, Lee YG, et al. Clinical course of non-severe aplastic anemia in adults. Int J Hematol. 2010; 91:770-5.
3. Peinemann F, Grouven U, Kröger N, Bartel C, Pittler MH, Lange S. First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. PLoS One 2011 25; 6:e18572.
4. Marsh JC. Management of acquired aplastic anemia. Blood Rev. 2005 May; 19:143-51.
5. Kojima S. Treatment of acquired aplastic anemia in children. Hematology. 2012;17(Suppl 1):S11-4.
6. Bacigalupo A. How I treat acquired aplastic anemia. Blood 2017;129:1428-36.
7. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants
for young patients with severe acquired aplastic anemia. Blood 2007 15;110:1397-400.
8. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430-8.
9. Narita A, Zhu X, Muramatsu H, et al. Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia. Br J Haematol 2019;187:227-37.
10. Pongtanakul B, Das PK, Charpentier K, Dror, Y. Outcome of children with aplastic anemia treated with immunosuppressive
therapy. Pediatr Blood cancer 2008;50:52-7
11. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N
Engl J Med 2017;376:1540-50
12. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl
J Med. 2012;367:11-9.
13. Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol 2019;6:e562-e572.
Downloads
Published
2020-09-28
Issue
Section
บทบรรณาธิการ (Editorial)
